Skip to main content
Gland Pharma Limited logo

Gland Pharma Limited — Investor Relations & Filings

Ticker · GLAND ISIN · INE068V01023 LEI · 335800JJVDY5R6KF5K34 BSE.NS Manufacturing
Open in API
Filings indexed 680 across all filing types
Latest filing 2022-01-28 Call Transcript
Country IN India
Listing BSE.NS GLAND

About Gland Pharma Limited

https://glandpharma.com

Gland Pharma Limited is a specialized Contract Development and Manufacturing Organization (CDMO) focused on injectable formulations. The company operates primarily through a business-to-business (B2B) model, providing development and manufacturing services for a diverse range of sterile injectables. Its portfolio encompasses complex generics across various therapeutic areas, including oncology, ophthalmology, anti-infectives, and orthopedics. Gland Pharma maintains a vertically integrated supply chain, ensuring control over critical raw materials and active pharmaceutical ingredients. The company serves a global market, with a significant presence in regulated regions such as the United States, Europe, Canada, and Australia. Its manufacturing facilities adhere to international quality standards and hold approvals from major regulatory bodies. Key strengths include expertise in niche segments like heparin and enoxaparin, alongside a robust pipeline of complex delivery systems.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is titled 'Earnings call Transcript- Q3FY22' and contains a detailed transcript of the company's earnings conference call for the third quarter of fiscal year 2022. It includes management's opening remarks, financial performance overview, business highlights, R&D progress, and a Q&A session. The content is a full text transcript of the earnings call, not just an announcement or summary. Therefore, the document fits the category of a Call Transcript (CT).
2022-01-28 English
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation Classification · 90% confidence The document is a letter addressed to stock exchanges notifying them of the schedule of analyst and institutional investor meetings. It references compliance with SEBI regulations and provides dates and types of meetings but contains no financial data, no report content, and no detailed presentation materials. The document is an announcement of upcoming investor meetings rather than the meetings' content or transcript. Therefore, it fits best under Investor Presentation (IP) category as it relates to investor communications and presentations, even though it is a schedule notice rather than the presentation itself. Given the short length and nature, it is not a full report or transcript. Confidence is high due to clear context and regulatory references.
2022-01-24 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the publication of a newspaper advertisement for unaudited financial results for Q3 FY 2022. It references Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, which mandates disclosure of financial results. The document contains no actual financial statements or detailed financial analysis, only a notification that the advertisement of the unaudited results has been published in newspapers. The document length is short (1644 characters), and it serves as an announcement rather than the financial report itself. Therefore, it fits best as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not contain substantive financial data.
2022-01-22 English
Monitoring Agency Report
Capital/Financing Update Classification · 95% confidence The document is titled 'Report of the Monitoring Agency for the Quarter ending December 31, 2021' and is issued pursuant to SEBI regulations related to the utilization of IPO proceeds. It is a detailed report from a monitoring agency (Axis Bank Limited) about the use of funds raised in an Initial Public Offering (IPO) by Gland Pharma Limited. The report includes financial details about the issue proceeds, their utilization, and investments of unutilized proceeds. The document is about monitoring the use of capital raised and compliance with regulatory requirements, not a general financial report or earnings release. It is not an announcement of a report but the report itself, with substantive financial data and analysis related to capital utilization. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes, including monitoring reports on IPO proceeds utilization.
2022-01-21 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is titled 'Investor Presentation on the Financial Results' and dated January 21, 2022. It contains detailed financial highlights for the quarter and nine months ended December 31, 2021, including revenue, EBITDA, PBT, PAT, segment revenue breakdowns, and operational updates. The text includes forward-looking statements, detailed financial metrics, and strategic business updates typical of an investor presentation. There is no indication that this is a full annual or quarterly report, audit report, or earnings release summary. The document is comprehensive and exceeds 5,000 characters, containing substantive financial data and analysis. Therefore, it fits the definition of an Investor Presentation (IP).
2022-01-21 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release announcing the financial results for the third quarter and nine months ended December 31, 2021. It contains summarized financial data such as revenue, EBITDA, PAT, and market-wise revenue growth. It also mentions an upcoming earnings call to discuss these results. The document is not a full financial report but an initial announcement of quarterly financial results with key highlights. Therefore, it fits the definition of an Earnings Release (ER). The document length (9293 characters) and content confirm it is a detailed press release rather than a brief announcement or a full interim report with comprehensive financial statements. Q3 2022
2022-01-21 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.